Do we need RWE?
‘Unmet needs’
•
Rare diseases (i.e. tail of mutations in a given cancer) are a challenge
to perform standard clinical trials and RWE may help “approval”
•
Understand patterns of use of clinical trial advances
•
Increasing view-need to monitor the clinical value in routine practice
of economical investment in anti-cancer treatments
